Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DCPS | Q96C86 | 5/20 | 0.34 |
| ▸ | DHFR | P00374 | 5/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 3/20 | 0.33 |
| ▸ | GRK3 | P35626 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662183 | 1.00 | TLR8 (0.35) | TLR8CDK8CDK5ROCK1CLK4 | |
| SCHEMBL21712357 | 0.92 | TLR8 (0.43) | TLR8CDK8CDK5ROCK1CLK4 | |
| SCHEMBL30662197 | 0.92 | TLR8 (0.43) | TLR8CDK8CDK5ROCK1CLK4 | |
| SCHEMBL20547228 | 0.90 | TLR8 (0.36) | TLR8CDK8CDK5ROCK1CLK4 | |
| Hydrochloric Acid SCHEMBL30612948 | 0.89 | TLR8 (0.36) | TLR8CDK8CDK5ROCK1CLK4 | |
| Hydrochloric Acid SCHEMBL21712391 | 0.89 | TLR8 (0.36) | TLR8CDK8CDK5ROCK1CLK4 | |
| SCHEMBL30662199 | 0.86 | TLR8 (0.45) | TLR8CDK8CDK5ROCK1CLK4 | |
| SCHEMBL21712374 | 0.86 | TLR8 (0.45) | TLR8CDK8CDK5ROCK1CLK4 | |
| SCHEMBL21712361 | 0.85 | NCF1 (0.39) | TLR8CDK8CDK5ROCK1CLK4 | |
| SCHEMBL30662172 | 0.85 | NCF1 (0.39) | TLR8CDK8CDK5ROCK1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615539-B1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-09 | — | — | EP | claimed |
| US-11053240-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-07-06 | — | — | US | claimed |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-20 | — | — | US | claimed |
| CN-110637018-A | 2-amino-quinoline derivatives | 博笛生物科技有限公司 | 2019-12-31 | — | — | CN | claimed |
| US-11834448-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-12-05 | — | — | US | disclosed |
| US-11834448-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-12-05 | — | — | US | disclosed |
| US-11834448-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-12-05 | — | — | US | disclosed |
| EP-3615539-B1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-09 | — | — | EP | disclosed |
| EP-3615539-B1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-09 | — | — | EP | disclosed |
| US-11053240-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-07-06 | — | — | US | disclosed |
| US-11053240-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-07-06 | — | — | US | disclosed |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-20 | — | — | US | disclosed |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-20 | — | — | US | disclosed |
| CN-110637018-A | 2-amino-quinoline derivatives | 博笛生物科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053240-B2 | 2-amino-quinoline derivatives | TLR7, TLR8, TLR1 | TLR8 2/4885CDK8 124/4885CDK5 3039/4885 |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | TLR7, TLR8, TLR1 | TLR8 2/4885CDK8 124/4885CDK5 3039/4885 |
| US-11834448-B2 | 2-amino-quinoline derivatives | TLR7, TLR8, TLR1 | TLR8 2/4885CDK8 124/4885CDK5 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.